Charles River Laboratories and MEDIPOST sign non-exclusive MOU to advance GMP Testing Solutions.
Article excerpt
Highlighted: the sentence this signal was extracted from
Charles River Laboratories and MEDIPOST sign non-exclusive MOU to advance GMP Testing Solutions. Partnership showcases a forward-looking collaboration model that highlights advanced testing expertise WILMINGTON, Mass.-(BUSINESS WIRE)-$CRL #CDMO-Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe. "We are excited to deepen our partnership with MEDIPOST and collaborate with a top global cell therapy developer, assisting at both clinical and commercialization phases," said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. "By collaborating with industry leaders, we aim to expand GMP testing capabilities and help ensure that safe, compliant products reach patients more efficiently." Charles River will provide specialized expertise in biologics quality control, viral testing, release testing, and other GMP-compliant services...
Keep reading with a free account
The rest of this article, and every signal for Charles River Laboratories, is in your free account.
